CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Menu
Begin main content
Home About CADTH What We Do Programs and Services Drug Reimbursement Review dupilumab
Back to Programs and Services

Drug Reimbursement Review

dupilumab

Last Updated: October 29, 2020
Result type: Reports
Project Number: SR0667-000
Product Line: Reimbursement Review

Generic Name: dupilumab

Brand Name: Dupixent

Manufacturer: Sanofi Genzyme, a division of sanofi-aventis Canada Inc.

Therapeutic Area: Asthma

Indications: DUPIXENT™ is indicated an add-on maintenance treatment in patients aged 12 years and older with severe asthma with a type 2/eosinophilic phenotype or oral corticosteroid-dependent asthma.

Manufacturer Requested Reimbursement Criteria1: DUPIXENT™ is indicated an add-on maintenance treatment in patients aged 12 years and older with severe asthma with a type 2/eosinophilic phenotype or oral corticosteroid-dependent asthma.

Submission Type: Initial

Project Status: Pending

Call for patient/clinician input open: October 29, 2020

Call for patient/clinician input closed: December 17, 2020

Anticipated Date: November 26, 2020

Fee Schedule: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Submit Feedback